Erratum. Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Tri (Q53777921)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Erratum. Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Tri |
scientific article |
Statements
1 reference
Erratum. Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Tri (English)
1 reference
Julio Rosenstock
1 reference
Markolf Hanefeld
1 reference
George Grunberger
1 reference
Ronnie Aronson
1 reference
PierMarco Piatti
1 reference
Pierre Serusclat
1 reference
Xi Cheng
1 reference
Tianyue Zhou
1 reference
Elisabeth Niemoeller
1 reference
Elisabeth Souhami
1 reference
Melanie Davies
1 reference
LixiLan-O Trial Investigators
1 reference
18 April 2017
1 reference
1 reference
40
1 reference
809
1 reference
6
1 reference
Identifiers
1 reference
1 reference
1 reference